Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients

NCT ID: NCT00873353

Last Updated: 2010-08-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-31
• Study Completion Date: 2010-08-31

Brief Summary

The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.

Detailed Description

This efficacy will be determined by objective response rate following RECIST criteria.

Conditions

Metastatic Adenocarcinoma of the Pancreas

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Unique arm

6 cycles (3 weeks each one) of :

• capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
• erlotinib (Tarceva®) 150mg/day, oral. Days: every days

Group Type: EXPERIMENTAL

capecitabine + erlotinib

Intervention Type: DRUG

6 cycles (3 weeks each one) of :

• capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
• erlotinib (Tarceva®) 150mg/day, oral. Days: every days

Interventions

capecitabine + erlotinib

6 cycles (3 weeks each one) of :

• capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
• erlotinib (Tarceva®) 150mg/day, oral. Days: every days

Intervention Type: DRUG

Other Intervention Names

capecitabine (Xeloda®)y erlotinib (Tarceva®)

Eligibility Criteria

Inclusion Criteria

1. Ability to understand and willingness to sign a written informed consent

2. Informed consent signed by the patient

3. Age > 18 years old

4. Able to fulfill all criteria from the protocol

5. Performance status Karnofsky ≥ 60% (ECOG 0-2)

6. Life expectancy ≥ 12 weeks

7. Histologically or cytological (excluding endocrine pancreatic tumour), with metastatic (stage IV), following 6th edition of TNM classification

8. Measurable disease following RECIST criteria

9. Adequate bone marrow function as determined by:

• Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L
• Platelets: ≥ 100 x 109/L
• Hemoglobin: ≥ 9 g/dL.

10. Adequate liver function, as determined by:

• Serum bilirubin (total): ≤ 1,5 x LSN
• AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver metastasis ≤ 5 x LSN

11. Adequate renal function, as determined by:

• Clearance creatinine > 60.0 ml/min

12. Men or women potentially fertile (including postmenopausal women amenorrheic at least 24 months before the study) should use adequate contraceptive methods (oral contraceptives, intrauterine disposal, barrier methods together with spermicide or surgery sterilization)

Exclusion Criteria

1. Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III), following the TNM 6th edition classification. Patients with metastatic disease that relapse after the initial diagnosis of local or advance disease could be included in this study.

2. Evidence of medullary compression, carcinomatosis meningitis or brain metastasis. In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior inclusion.

3. Previous systemic treatment for metastasis pancreas cancer. Adjuvant chemotherapy is permitted ≥ 4 weeks prior de inclusion. All toxicities from the adjuvant treatment must been solve before the inclusion and should be confirmed the diseases progression (metastatic disease) alter adjuvant treatment

4. Primary tumours Developer 5 years previous to the inclusion, except in situ cérvix carcinoma or skin basocellular cancer properly treated

5. Non-controlled hypertension or cardiovascular disease clinically significant (active):

• Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion)
• Heart attack (≤ 6 months prior to inclusion)
• Instable angina
• Congestive cardiac insufficiency (grade II or superior following to New York Heart Association (NYHA)
• Severe cardiac arrhythmia that require medication

6. Significant ophthalmology anomalies

7. Deficit in dihydropyrimidine dehydrogenase (DPD)

8. Unable to take oral drug. Previous surgical process that affect the absorption or make the needed to have intravenous feeding or parenteral nutrition with lipids.

9. Pregnancy women or in latency period. Negative pregnancy test needed 7 days prior to initiation drug study

10. Actual or 30 days previous to study treatment with other investigational drug or participation in other trial

11. Previous treatment with Capecitabine or EGFR inhibitor.

12. Any other disease, metabolic disease

13. Known hypersensibility to any study drug or any of their component, or to 5-fluorouracile

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Grupo Gallego de Investigaciones Oncologicas

OTHER

Sponsor Role: lead

Responsible Party

Grupo Gallego de Investigaciones Oncologicas

Principal Investigators

Rafel López López, Coordinator

Role: STUDY_CHAIR

Grupo Gallego de Investigaciones Oncológicas

Locations

Complejo Hospitalario Universitario de La Coruña

A Coruña, La Coruña, Spain

Centro Oncológico de Galicia

A Coruña, La Coruña, Spain

Hospital Arquitecto Marcide

Ferrol, La Coruña, Spain

Complejo Hospitalario Xeral Calde

Lugo, Lugo, Spain

Complejo Hospitalario de Orense

Ourense, Orense, Spain

Hospital do Meixoeiro

Vigo, Vigo, Spain

Complejo Hospitalario Xeral Cies

Vigo, Vigo, Spain

Hospital POVISA

Vigo, Vigo, Spain

Countries

Spain

Other Identifiers

2007-003206-96

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ML21154

Identifier Type: -

Identifier Source: org_study_id